Highlights • We acquired FDG-PET, FMISO-PET, DW-MRI and DCE-MRI for 18 soft-tissue sarcomas.• We investigated the complementarity and evolution of imaging data over time.• We used textural biomarkers to identify… Click to show full abstract
Highlights • We acquired FDG-PET, FMISO-PET, DW-MRI and DCE-MRI for 18 soft-tissue sarcomas.• We investigated the complementarity and evolution of imaging data over time.• We used textural biomarkers to identify patients who could benefit from dose boosts.• We showed the technical feasibility of double boost doses to sub-GTV regions.
               
Click one of the above tabs to view related content.